Financials (USD)
Sales 2024 * | 529M | Sales 2025 * | 681M | Capitalization | 2.96B |
---|---|---|---|---|---|
Net income 2024 * | -1M | Net income 2025 * | 120M | EV / Sales 2024 * | 5.86 x |
Net Debt 2024 * | 139M | Net Debt 2025 * | 24.31M | EV / Sales 2025 * | 4.38 x |
P/E ratio 2024 * |
-1,646
x | P/E ratio 2025 * |
25.8
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 89.81% |
Latest transcript on Amicus Therapeutics
Managers | Title | Age | Since |
---|---|---|---|
Bradley Campbell
CEO | Chief Executive Officer | 48 | 06-03-31 |
Simon Harford
DFI | Director of Finance/CFO | 64 | 23-08-20 |
Pat O’Sullivan
COO | Chief Operating Officer | - | 22-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bradley Campbell
CEO | Chief Executive Officer | 48 | 06-03-31 |
Lynn Bleil
BRD | Director/Board Member | 60 | 18-09-10 |
Burke W. Whitman
BRD | Director/Board Member | 68 | 19-06-26 |
1st Jan change | Capi. | |
---|---|---|
+0.17% | 42.19B | |
+10.92% | 42.24B | |
+44.30% | 40.15B | |
-6.20% | 28.31B | |
+5.23% | 24.63B | |
-24.79% | 18.2B | |
+26.69% | 12.01B | |
-3.13% | 11.76B | |
+6.57% | 10.4B |